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Abstract
Background:  Cholangiocellular cancers account for about 10-15% of primary liver cancers.
Prognosis is poor, with expected survival of less than 5% at five-year.
Case presentation: The case described shows remission of a disseminated cholangiocellular
carcinoma (focal changes in liver, metastases to lungs) after neoadjuvant chemotherapy. The initial
diagnosis was based on ultrasound examination and confirmed with computer tomography.
Tumour biopsy and histopathological examination revealed cholangiocellular carcinoma. The
patient underwent chemotherapy. After remission of lesions in lungs and reduction/regression of
tumours in liver to one focal change, right lobe liver resection was performed. The
histopathological examination did not reveal any viable carcinoma cells, only necrotic tissues in
place of the primary tumour as well as in local portal vein branches was seen. Thirty months after
the operation the patient is in a good overall condition and no recurrence has been observed.
Conclusion: Appropriate neoadjuvant chemotherapy may allow radical resection in a previously
unresectable cholangiocellular cancer.
Background
Intrahepatic cholangiocarcinoma (CCC) is a rare liver
malignancy constituting about 10–15% of all primary
liver cancers. It is far less common than hepatocellular car-
cinoma (HCC) which constitute over 80% of primary
liver cancers [1,2]. While surgical therapy is the most effec-
tive treatment, only 25% of patients are resectable at pres-
entation as CCC is often diagnosed in advanced,
nonresectable stages [3,4]. Advanced CCC is associated
with particularly poor prognosis, as chemotherapy and
radiotherapy have a very limited impact on the disease.
We describe a case of CCC that could be resected after
downstaging with neoadjuvant chemotherapy.
Case presentation
In September 2003, a 33-year-old patient was admitted to
internal diseases clinic. He had a 2-month history of pain
in right upper abdomen radiating to thoracic spine and
weight loss (30 kg within 2 months). There were no
abnormal signs in physical examination, biochemical
tests were within normal range.
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Computed tomography (CT) revealed multiple focal
changes in liver, the largest lesion in the right lobe was 9.2
× 4.5 × 7 cm, and metastases in lungs (Figure 1). Gastros-
copy and colonoscopy did not show any digestive tract
tumours. Needle biopsy of the tumour showed low-differ-
entiated intrahepatic cholangiocarcinoma. Based on these
results, patient was qualified for palliative systemic chem-
otherapy treatment (PIAF scheme) was started on
29.10.2003. The details of the doses and schedule are
given in Table 1.
In December 2003, after 3 courses of chemotherapy,
repeat CT scan showed partial remission of the neoplastic
disease, after 6 courses further remission was visible on CT
examination.
Computed tomography after 9 courses of chemotherapy
in May 2004 showed reduction of primary tumour as well
as regression of metastases in lungs and other lesions in
liver (Figure 2). Patient was qualified for operative treat-
ment and in June 2004, right hemihepatectomy was per-
formed. The postoperative period was without
complications, patient was discharged from hospital 8
days after operation in good general condition.
Postoperative histopathological examination showed
tumour, 26 mm in greatest diameter, encapsulated, with
necrotic masses inside capsule. In the surroundings of the
tumour necrotic focal change with similar morphology,
without capsule was found. No viable tumour cells were
found, in surrounding vessels necrotic masses embolisms
were found. Morphology suggested cholangiocarcinoma
(Figure 3, 4)
After the operation patient received remaining two
courses of chemotherapy. Adverse effects included mild
leucopenia, thrombocytopenia (80000/µl), mild increase
in alkaline phosphatase (200 U/l) and alopecia. Repeat
CT scan in August 2004 showed regeneration of liver
parenchyma, there was no sign of recurrence of the neo-
plasm. Control examinations 12, 18, 24 and 29 months
after operation did not show any signs of recurrence.
Discussion
Resection is the preferred treatment in the management of
CCC; patients with resected CCC are the only long-term
survivors [5-8]. The precise results differ depending on
tumour stage, general condition of the patient and non-
operative method applied. Chemoembolization gives bet-
ter results than systemic chemotherapy, however, in
patients with disease as advanced as the described case it
is not applicable. Patients with metastases are considered
to have particularly poor prognosis, median survivals in
such cases is below 8 months. [9]
Effectiveness of chemotherapy is unsatisfactory - less than
30% responses to treatment, usually it does not signifi-
cantly improve the prognosis. Currently, phase III clinical
trials using Gemcitabine had been conducted and col-
lected data allows expecting more encouraging results. [9-
11]
Various chemotherapy regimes based on 5-FU in combi-
nation with cisplatin, interferon, and doxorubicin were
reported to be active in CCC [12-15]. Although chemo-
therapy regimens containing platinum analogs have
reported higher response rates (20–40%), their toxicity is
considerable, especially myelosuppression and gastroin-
testinal upset [16,17]. PIAF regimen is reported to pro-
duce some dramatic anti tumour responses, yet it is
uncertain if it can be indicated for all patients with
cholangiocarcinoma because of its toxicity [18]. The case
described presents advanced cholangiocarcinoma.
Numerous focal changes in liver and metastases to lungs
visible in computed tomography indicates that the proc-
ess was highly advanced. TNM staging was T4 Nx M1
(IVb). Performing a curative resection was impossible in
such an advanced stage. The chemotherapy regimen was
chosen as a salvage treatment considering young age of
the patient and advanced stage of the neoplasm. Systemic
chemotherapy induced total remission of metastases in
lungs and reduction of changes in liver to one tumour in
right lobe, which allowed radical resection. It is uncertain
why such a good response to chemotherapy occurred in
case of tumour considered to be chemoresistant. PIAF reg-
imen was relatively well tolerated by the patient, which
can be attributed to his young age and good overall con-
dition.
Table 1: Drug name and mode of administration
date (day of chth)
(I day) 1. Doxorubicin 80 mg i.v.
2. Cis-Platinium 40 mg i.v.
3. 5-FU 800 mg i.v.
4. Roferon 9 MU
(II day) 1. Cis-Platinium 40 mg i.v.
2. 5-FU 800 mg i.v.
3. Roferon 9 M U
(III day) 1. Cis-Platinium 40 mg i.v.
2. 5-FU 800 mg i.v.
3. Roferon 9 M U
(IV day) 1. Cis-Platinium 40 mg i.v.
2. 5-FU 800 mg i.v.
3. Roferon 9 M U
PIAF chemotherapy scheme. Patient body surface area 2 m2.
5-FU – 5-Fluorouracil
Roferon – Interferon KWorld Journal of Surgical Oncology 2007, 5:36 http://www.wjso.com/content/5/1/36
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Computed tomography, A – multiple focal changes in liver are visible, B – multiple metastases to lungs are visible Figure 1
Computed tomography, A – multiple focal changes in liver are visible, B – multiple metastases to lungs are visible.
Computed tomography after chemotherapy A – regression of focal changes in liver is visible B – regression of metastases in  lungs is visible Figure 2
Computed tomography after chemotherapy A – regression of focal changes in liver is visible B – regression of metastases in 
lungs is visible.World Journal of Surgical Oncology 2007, 5:36 http://www.wjso.com/content/5/1/36
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Histopathological specimen of resected liver tumour, 200× Figure 3
Histopathological specimen of resected liver tumour, 200×. Necrotic masses embolism inside a portal vein branch.
Histopathological specimen of resected liver tumour, 200× Figure 4
Histopathological specimen of resected liver tumour, 200×. Necrotic masses within the tumour.Publish with BioMed Central    and   every 
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Necrosis was the only remaining focal change in liver
along with presence of necrotic masses in portal vein
branches around the tumour – this can be considered as a
proof of chemotherapy effectiveness. Thirty months after
operation patient is in good general condition and shows
no sign of disease recurrence.
Conclusion
The unusually good response of the neoplasm to chemo-
therapy is worth reporting, especially because systemic
chemotherapy is considered little or non effective in dis-
seminated cholangiocellular carcinoma and there is still
no established protocol for it. Although this chemother-
apy regimen can not be recommended as a treatment in
case of CCC basing on a single case report, this patient's
response shows that therapy of an advanced CCC is possi-
ble. This case may suggest that the chemotherapy scheme
described could be considered as a therapy option for cer-
tain patients with advanced cholangiocellular carcinoma,
possibly young ones who are more likely to tolerate the
toxicity of this regimen.
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